Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy

Oncopeptides AB

27/08/2026 07:17

Overview
Sweden biotech firm's Q2 net sales rose 62% yr/yr to SEK 31.1 mln
Q2 net loss and loss per share narrowed from prior year
Company advanced Pepaxti label expansion and began glioblastoma study

Outlook
Oncopeptides remains on track to achieve positive cash flow during 2027
Company expects country-level profitability in Germany for full yr 2026
Oncopeptides anticipates CHMP opinion on Pepaxti label expansion between Sep-Nov 2026

Result Drivers
EUROPEAN MARKET PERFORMANCE - Co said Italy performed well above expectations and Spain regained sales momentum, with June reaching all-time high
DISTRIBUTION AGREEMENT - Co signed partnership with Salus Group for Pepaxti in Central and Eastern Europe, enabling earlier regional demand
REGULATORY MILESTONES - Co submitted Type II variation application to EMA to expand Pepaxti indication and received approval for glioblastoma study in Norway

Company press release: ID:nMFN3ddqd3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 31.10 mln
 
Q2 Adjusted Loss Per Share
 
SEK 0.14
 
Q2 Net Loss
 
SEK 54.71 mln
 
Q2 Operating Profit
 
-SEK 48.67 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Oncopeptides AB is SEK2.30, about 35.1% above its August 26 closing price of SEK1.70

Reuters Recommended Reads
Aug 26 - Sweden's AlzeCure Pharma Q2 net sales surge on licensing deals
Aug 26 - Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Aug 26 - Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)